12 August 2020 : Clinical Research
Effect of 2 Different Dosages of Rosuvastatin on Prognosis of Acute Myocardial Infarction Patients with New-Onset Atrial Fibrillation in Jinan, ChinaJie Zhang12ABCDEFG, Ruiqi Feng3DEF, Misbahul Ferdous45DEF, Bo Dong5BCDG, Haitao Yuan5ABCDF, Peng Zhao5ABCDEFG*
Med Sci Monit 2020; 26:e925666
BACKGROUND: Atrial fibrillation (AF) often occurs in patients with acute myocardial infarction (AMI). This study aimed to observe the influence of different dosages of rosuvastatin on the prognosis of AMI patients with AF.
MATERIAL AND METHODS: We performed an observational, retrospective cohort study in Jinan, China, in which 323 AMI patients were recruited. All patients were randomized to receive optimal medication treatment and 10 mg or 20 mg of rosuvastatin. Holter monitor results, serum lipid levels, and heart function were recorded. We used multivariate Cox and Kaplan-Meier analyses to assess the independent factors and differences in AF and ischemia events and safety of rosuvastatin administered at different dosages.
RESULTS: TC, LDL-C, and TG at 1 and 12 months were significantly lower compared with those observed prior to treatment in both groups. The heart function of both groups was significantly improved after 12 months of treatment, especially in the 20 mg group. Multivariate Cox analysis showed that different dosages of rosuvastatin, age, smoking, drinking alcohol, and diabetes are independent factors related to the occurrence of AF and ischemic events. In addition, according to Kaplan-Meier analysis, no significant difference in adverse clinical events existed at different dosages of rosuvastatin.
CONCLUSIONS: Treatment with rosuvastatin can reduce the serum lipid level and improve cardiac function. Different dosages of rosuvastatin, age, smoking, drinking alcohol, and diabetes are independent risk factors for AF and ischemia events. The results suggested it is safe to use 20 mg rosuvastatin in the 12 months after hospital admission.
Keywords: Atrial Fibrillation, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Myocardial Infarction
This Week Editorial
02 August 2021 : EditorialEditorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19
Med Sci Monit 2021; 27:e934171
30 July 2021 : Clinical ResearchRural and Female Patients with Old Myocardial Infarction Lacked Knowledge and Preventive Measures During th...
Med Sci Monit In Press :: DOI: 10.12659/MSM.928512
16 July 2021 : Review articleSilent Hypoxemia in Patients with COVID-19 Pneumonia: A Review
Med Sci Monit In Press :: DOI: 10.12659/MSM.930776
09 July 2021 : Database AnalysisA Simple Clinical Prediction Tool for COVID-19 in Primary Care with Epidemiology: Temperature-Leukocytes-CT...
Med Sci Monit In Press :: DOI: 10.12659/MSM.931467
03 Aug 2021 : Clinical ResearchComparison of Outcomes Following TiRobot-Assisted Sacroiliac Screw Fixation with Bone Grafting and Traditio...
Med Sci Monit In Press :: DOI: 10.12659/MSM.932724
02 Aug 2021 : Database AnalysisRNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape...
Med Sci Monit In Press :: DOI: 10.12659/MSM.930994
02 Aug 2021 : Clinical ResearchVitamin D Receptor Is a Sepsis-Susceptibility Gene in Chinese Children
Med Sci Monit In Press :: DOI: 10.12659/MSM.932518
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700